Drug Profile
Merimepodib - NeuroClear Technologies
Alternative Names: Merimempodib; MMPD; VI-21,497; Vicromax™; VX-497Latest Information Update: 29 Oct 2020
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer NeuroClear Technologies; Vertex Pharmaceuticals; ViralClear Pharmaceuticals
- Class Amines; Antiasthmatics; Antipsoriatics; Antirheumatics; Antivirals; Carbamates; Furans; Oxazoles; Phenylurea compounds; Small molecules
- Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections; Hepatitis C; Psoriasis